Helena Ramos

Dr. Helena Ramos

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Pharmacological Research
Verified
Journal Article
Closed access
AGAna Sara Gomes
Ana Sara Gomes
HRHelena Ramos
Helena Ramos
JSJoana Soares
Joana Soares
Lucília SaraivaLucília Saraiva
Lucília Saraiva

3 July 2021 in Cancers
Verified
Journal Article
Open access
PDF file
AGAna Sara Gomes
Ana Sara Gomes
HRHelena Ramos
Helena Ramos
Alberto IngaAlberto Inga
Alberto Inga
Maria Emília SousaMaria Emília Sousa
Maria Emília Sousa
Lucília SaraivaLucília Saraiva
Lucília Saraiva
P53 is a transcription factor with a pivotal role in cell homeostasis and fate. Its impairment is a major event in tumor onset and development. In fact, about half of human cancers bear TP53 mutations that not only halt the normal function of p53, but also may acquire oncogenic gain of functions that favor tumorigenesis. Although considered undruggable for a long time, evidence has proven the capability of many compounds to restore a wild-type (wt)-like function to mutant p53 (mutp53). However, they have not reached the clinic to date. Structural studies have strongly contributed to the knowledge about p53 structure, stability, dynamics, function, and regulation. Importantly, they have afforded relevant insights into wt and mutp53 pharmacology at molecular levels, fostering the design and development of p53-targeted anticancer therapies. Herein, we provide an integrated view of mutp53 regulation, particularly focusing on mutp53 structural traits and on targeting agents capable of its reactivation, including their biological, biochemical and biophysical features. With this, we expect to pave the way for the development of improved small molecules that may advance precision cancer therapy by targeting p53.

2 May 2017 in Molecular Oncology
Verified
Journal Article
Open access
PDF file
JSJoana Soares
Joana Soares
MEMargarida Espadinha
Margarida Espadinha
LRLiliana Raimundo
Liliana Raimundo
HRHelena Ramos
Helena Ramos
AGAna Sara Gomes
Ana Sara Gomes
Lucília SaraivaLucília Saraiva
Lucília Saraiva
The transcription factor p53 plays a crucial role in cancer development and dissemination, and thus, p53-targeted therapies are among the most encouraging anticancer strategies. In human cancers with wild-type (wt) p53, its inactivation by interaction with murine double minute (MDM)2 and MDMX is a common event. Simultaneous inhibition of the p53 interaction with both MDMs is crucial to restore the tumor suppressor activity of p53. Here, we describe the synthesis of the new tryptophanol-derived oxazoloisoindolinone DIMP53-1 and identify its activity as a dual inhibitor of the p53–MDM2/X interactions using a yeast-based assay. DIMP53-1 caused growth inhibition, mediated by p53 stabilization and upregulation of p53 transcriptional targets involved in cell cycle arrest and apoptosis, in wt p53-expressing tumor cells, including MDM2- or MDMX-overexpressing cells. Importantly, DIMP53-1 inhibits the p53–MDM2/X interactions by potentially binding to p53, in human colon adenocarcinoma HCT116 cells. DIMP53-1 also inhibited the migration and invasion of HCT116 cells, and the migration and tube formation of HMVEC-D endothelial cells. Notably, in human tumor xenograft mice models, DIMP53-1 showed a p53-dependent antitumor activity through induction of apoptosis and inhibition of proliferation and angiogenesis. Finally, no genotoxicity or undesirable toxic effects were observed with DIMP53-1. In conclusion, DIMP53-1 is a novel p53 activator, which potentially binds to p53 inhibiting its interaction with MDM2 and MDMX. Although target-directed, DIMP53-1 has a multifunctional activity, targeting major hallmarks of cancer through its antiproliferative, proapoptotic, antiangiogenic, anti-invasive, and antimigratory properties. DIMP53-1 is a promising anticancer drug candidate and an encouraging starting point to develop improved derivatives for clinical application.

1 April 2019 in Cancer Letters
Verified
Journal Article
Closed access
SGSara Gomes
Sara Gomes
LRLiliana Raimundo
Liliana Raimundo
JSJoana Soares
Joana Soares
JLJoana Loureiro
Joana Loureiro
MLMariana Leão
Mariana Leão
Lucília SaraivaLucília Saraiva
Lucília Saraiva

25 October 2020 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
Marta Hernández-GarcíaMarta Hernández-García
Marta Hernández-García
MGMaría García-Castillo
María García-Castillo
SGSergio García-Fernández
Sergio García-Fernández
JMJosé Melo-Cristino
José Melo-Cristino
MPMargarida F Pinto
Margarida F Pinto
CMCarolina Moura
Carolina Moura
Objectives: To analyse the epidemiology, the resistome and the virulome of ceftolozane/tazobactam-susceptible or -resistant Pseudomonas aeruginosa clinical isolates recovered from surveillance studies in Portugal (STEP, 2017–18) and Spain (SUPERIOR, 2016–17).Methods: P. aeruginosa isolates were recovered from intra-abdominal, urinary tract and lower respiratory tract infections in ICU patients admitted to 11 Portuguese and 8 Spanish hospitals. MICs were determined (ISO-standard broth microdilution, EUCAST 2020 breakpoints). A subset of 28 ceftolozane/tazobactam-resistant P. aeruginosa isolates were analysed and compared with 28 ceftolozane/tazobactam-susceptible P. aeruginosa strains by WGS.Results: Clonal complex (CC) 235 (27%) and CC175 (18%) were the most frequent, followed by CC244 (13%), CC348 (9%), CC253 (5%) and CC309 (5%). Inter-hospital clonal dissemination was observed, limited to a geographical region (CC235, CC244, CC348 and CC253 in Portugal and CC175 and CC309 in Spain). Carbapenemases were detected in 25 isolates (45%): GES-13 (13/25); VIM type (10/25) [VIM-2 (4/10), VIM-20 (3/10), VIM-1 (2/10) and VIM-36 (1/10)]; and KPC-3 (2/25). GES-13-CC235 (13/15) and VIM type-CC175 (5/10) associations were observed. Interestingly, KPC-3 and VIM-36 producers showed ceftolozane/tazobactam-susceptible phenotypes. However, ceftolozane/tazobactam resistance was significantly associated with GES-13 and VIM-type carbapenemase production. Six non-carbapenemase producers also displayed ceftolozane/tazobactam resistance, three of them showing known ceftolozane/tazobactam resistance-associated mutations in the PBP3 gene, ftsI (R504C and F533L). Overall, an extensive virulome was identified in all P. aeruginosa isolates, particularly in carbapenemase-producing strains.Conclusions: GES-13-CC235 and VIM type-CC175 were the most frequent MDR/XDR P. aeruginosa clones causing infections in Portuguese and Spanish ICU patients, respectively. Ceftolozane/tazobactam resistance was mainly due to carbapenemase production, although mutations in PBP-encoding genes may additionally be involved.

1 December 2015 in Life Sciences
Verified
Journal Article
Closed access
MLMariana Leão
Mariana Leão
JSJoana Soares
Joana Soares
SGSara Gomes
Sara Gomes
LRLiliana Raimundo
Liliana Raimundo
HRHelena Ramos
Helena Ramos
Lucília SaraivaLucília Saraiva
Lucília Saraiva